| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.08 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.09 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.067 | 0.09 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.09 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | Vorinostat | CTRPv2 | pan-cancer | AAC | 0.059 | 0.09 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.067 | 0.1 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.1 |